Contact Us

Request a Demo

Condition

CML(1)

Imatinib Intolerant(1)

Imatinib Resistant(1)

Overall Status

Completed(1)

Phase

phase 4(1)

Sponsor New

Novartis Pharmaceuticals(1)

Intervention New

nilotinib(1)

Study Results

Has Results

Study Documents

Intervention Type

drug(1)

Funder Type

Industry(1)

Study Type

Interventional(1)

Age Group

Any

Youth (0 - 17 years)

Adult (18 - 64 years)

Older Adult (65+ years)

Gender

all(1)

City

Imatinib Intolerant Clinical Trials

Create an account to Download

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

N

Tasigna in Glivec-resistant or Intolerant Patients in CML - 2012

Completed

CML
+3 more

nilotinib

Seoul, Korea, Republic of
St. Mary hospital, Catholic medical center

2017-02-24

Feb 24, 2017

Do More

Create up to 2 groups of studies for comparison and sharing
Get notified when studies are updated
Download tabulated search results instantly
Unlimited searches

Sign UpNot Today

2022 © Clincosm, Inc.

Exploring the universe of clinical trials just got cosmically easier.

Newest Clinical Trials